IL6 and myelodysplastic syndrome: A phase II, randomized, double-blind multicenter study comparing anti–IL-6 effects with placebo in anemic patients with International Prognostic Scoring System low- or intermediate-1–risk MDS showed no reduction in red blood cell transfusions in transfusion-dependent patients (50).